ClinicalTrials.gg
RecruitingNCT07205822TB06Updated Oct 2, 2026

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

A Phase 3 interventional study of Dato-DXd in Breast Cancer, sponsored by AstraZeneca. Recruiting at 40 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Oct 2, 2026Site recruiting status changedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing datopotamab deruxtecan in Breast Neoplasms — 8 open to participants now, 14 under way, 6 of them phase 3. datopotamab deruxtecan · Breast Neoplasms.

Planned enrollment
10th of 14
100 · median 300
Started
2025
the only one that year
Phase 3
6 of 14
2 open now
Primary completion
2028-02
later than 10 of 13 live
Registered
13th of 14
by date
Lead sponsor
7 of 14
AstraZeneca

Among the 14 studies testing datopotamab deruxtecan in Breast Neoplasms, this one is the 10th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 3, reaches primary completion later than 10 of the 13 other live ones, and was the 13th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing datopotamab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing datopotamab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.

Read the detailed description

This is a Phase IIIb, single-arm, open-label, multicentre, multinational study assessing the efficacy and safety of Dato-DXd in participants with HR-positive, HER2 IHC 0, locally advanced inoperable or metastatic breast cancer refractory to endocrine therapy.

Refer to the study schema (Figure 1) and SoA (Section 1.3) for overall design and required assessments. Day 1 is defined as the first day of study treatment.

Approximately 100 participants will be treated in this study with Dato-DXd 6 mg/kg as an intravenous infusion every 3 weeks (21-day cycle), up to a maximum of 540 mg for patients ≥ 90kg. Participants will receive study intervention until RECIST 1.1 defined radiological progression by investigator unless there is evidence of unacceptable toxicity or if the participant requests to stop the study treatment.

Written consent is required from all participants for newly acquired tumour biopsy collection at baseline or for the latest available archival tumour sample when a fresh biopsy is not feasible prior to initiating Dato-DXd and, if feasible, at progression. This sample will be used to assess for HER2 and TROP2 expression and exploratory analysis of biomarkers of response. Participants are also expected to consent for repeated liquid biopsy at baseline, during the treatment period, and at progression to evaluate biomarkers of response and resistance. (Sample collection in China will comply with local regulatory requirements.) Tumour imaging will occur every 8 weeks (± 1 week) after the first dose of study drug for 48 weeks and then every 12 weeks (± 1 week) thereafter until RECIST 1.1 disease progression as assessed by the investigator or the start of subsequent anticancer therapy.

03

Conditions studied

  • Breast Cancer

Keywords

  • HR+, HER2 IHC 0, LA Inoperable/Metastatic, Endo Refractory
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years (and above legal age) at the time of screening.
  2. Inoperable or HR-positive, IHC 0 breast cancer (per ASCO/CAP guidelines, on local laboratory results); ie, is documented as HR-positive (either ER and/or PgR positive [ER or PgR ≥ 1%]) and HER2 IHC 0 (defined as including HER2 null with no staining or incomplete and faint/barely perceptible membrane staining in ≤ 10% of tumour cells) based on a fresh, or recent tissue sample. Tumour status must be confirmed using the most recent tumour (preferably fresh biopsy).

    A fresh biopsy may only be omitted if not medically feasible due to documented clinical reasons, such as anatomical inaccessibility, unacceptable procedural risk, or patient refusal after appropriate discussion. In such cases, the most recent available tumour sample may be used. The specific reason for not obtaining a fresh biopsy must be prospectively documented and may be subject to sponsor review.

  3. Progressed on and not suitable for further endocrine therapy per investigator assessment.
  4. performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to the first dose of study intervention.
  5. Minimum of 12 weeks at screening.
  6. Provision of acceptable tumour sample (newly acquired tumour biopsy at baseline or the latest archival biopsy available if a fresh biopsy is not feasible) as defined in the Laboratory Manual
  7. Participants must have as per 1.1 or evaluable disease. Lesions that will be subject to mandatory biopsy before, during, and after the dosing cannot be considered as TLs as per RECIST requirements.
  8. Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention.

    1. ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
    2. ≥ 1.5×109/L (granulocyte colony stimulating factor administration is not allowed within 1 week prior to screening assessment).
    3. count ≥ 100×109/L (platelet transfusion is not allowed within 1 week prior to screening assessment).
    4. Serum albumin ≥ 2.5 g/dL.
    5. TBL ≤ 1.5 × or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinaemia).
    6. Except in the setting of , and AST ≤ 2.5 × ULN; for participants with hepatic metastases, ALT and AST ≤ 5 × ULN. See Exclusion Criterion 8 for requirements in the setting of HBV.
    7. Calculated CrCL ≥ 30 mL/min as determined by (using actual body weight).
  9. Male and/or female assigned at birth, inclusive of all gender identities.
  10. use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies;

    (a) Male participants: (i) Use of a condom plus an additional contraceptive method, or avoid intercourse throughout the duration of treatment and for at least 4 months after the last dose of Dato-DXd, in addition to the female partner using a highly effective contraceptive method.

    (ii) Starting at the time of first dose of Dato-DXd, male participants must not freeze or donate sperm throughout the duration of treatment and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to the first dose of study intervention.

    (b) Female participants:Female participants not of (ii) Female participants receiving HRT and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for WOCBP if they wish to continue using HRT during the study. Otherwise, HRT must be discontinued to allow confirmation of status prior to study enrolment; (iii) WOCBP must use one highly effective form of contraception or avoid intercourse throughout the duration of treatment and for at least 7 months after the last dose of Dato-DXd. All WOCBP must have a negative serum pregnancy test documented during screening.

    (iv) Starting at the time of first dose of Dato-DXd, female participants must not donate, or retrieve for their own use, ova throughout the duration of treatment and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to the first dose of study intervention.

  11. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICF and in this CSP.
  12. All races, genders, and ethnic groups are eligible for this study.

Exclusion criteria

Exclusion Criteria:

  1. As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including active bleeding diseases and ongoing or active infection), history of allogenic organ transplant, and/or substance abuse which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
  2. History of another primary except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non melanoma skin cancer (basal cell carcinoma of the skin or squamous cell carcinoma of the skin) and curatively treated in situ disease.
  3. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Note: participants may be enrolled with some chronic, stable Grade 2 toxicities (defined as no worsening to Grade > 2 for at least 3 months prior to the first dose of study intervention and managed with SoC treatment) which the investigator deems related to previous anticancer therapy):

    1. Chemotherapy-induced neuropathy
    2. Fatigue
    3. Residual toxicities from prior immunotherapy treatment: Grade 1 or Grade 2 endocrinopathies, which may include but are not limited to hypothyroidism/hyperthyroidism, Type I diabetes, hyperglycaemia, adrenal insufficiency, or adrenalitis; and skin hypopigmentation (vitiligo) Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention in the opinion of the investigator may be included (eg, hearing loss).
  4. Spinal cord compression or (unless asymptomatic, stable, and not requiring treatment with or anticonvulsants for at least 2 weeks prior to the first dose of study intervention). Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants must have recovered from the acute toxic effect of radiotherapy (eg, dizziness and signs of increased intracranial pressure). A minimum of 2 weeks must have elapsed between the end of brain radiotherapy and the first dose of study intervention. A minimum of 3 days must have elapsed between the end of corticosteroid therapy for CNS disease and the first dose of study intervention.
  5. or metastasis.
  6. Has significant third-space fluid retention (eg, ascites or pleural effusion) and is not amenable for required repeated drainage.
  7. corneal disease.
  8. Has active or uncontrolled or C virus infection. Participants are eligible if they:

    1. Have been curatively treated for infection as demonstrated clinically and by viral serologies
    2. Have received HBV vaccination with only anti-HBs positivity and no clinical signs of hepatitis
    3. Are HBsAg- and anti-HBc+ (ie, those who have cleared HBV after infection) and meet conditions i-iii of criterion 'd' below:
    4. Are HBsAg+ with chronic HBV infection (lasting 6 months or longer) and meet conditions i-iii below:

    (i) HBV DNA viral load \< 2000 IU/mL (ii) Have normal transaminase values or, if liver metastases are present, abnormal transaminases, with a result of /ALT \< 3 × , which are not attributable to HBV infection (iii) Start or maintain antiviral treatment if clinically indicated as per the investigator

  9. Known infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, ≥ 350, no history of AIDS defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended. Participants must be tested for HIV during the screening period if acceptable by local regulations or an IRB/EC.
  10. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localised fungal infections of skin or nails are eligible).
  11. Known to have active tuberculosis infection (clinical evaluation that may include clinical history, physical examination, and radiographic findings, or tuberculosis testing in line with local practice).
  12. Resting with clinically abnormal findings.
  13. Uncontrolled or significant cardiac disease including:

    1. Myocardial infarction or uncontrolled/unstable angina within 6 months before the first dose of study intervention.
    2. Congestive heart failure ( Class II to IV).
    3. Uncontrolled hypertension (resting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg).
    4. Cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment ( Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted based on the investigator judgement with cardiologist consultation recommended.
  14. History of non-infectious ILD/pneumonitis, including radiation pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  15. Has clinically severe pulmonary function compromise (ie, requiring any supplemental oxygen), resulting from intercurrent pulmonary illnesses including but not limited to the following:

    1. Any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the trial enrolment, severe asthma, severe , restrictive lung disease, pleural effusion, etc)
    2. Any , connective tissue, or inflammatory disorder with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc)
    3. Prior pneumonectomy
  16. Prior exposure to the following anticancer therapies:

    1. Any TROP2-targeted therapy.
    2. Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I.
    3. Any chemotherapy in the metastatic setting.
  17. Prior exposure to chloroquine/hydroxychloroquine without an adequate treatment of > 14 days before the first dose of study intervention.
  18. Receipt of the last dose of anticancer therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, tumour embolisation, or monoclonal antibodies ≤ 3 weeks [for small molecule targeted agents: ≤ 2 weeks or 5 half-lives, whichever is longer, prior to the first dose of study intervention]). Herbal or natural products intended as treatment or prophylaxis for any type of cancer that may interfere with the activity of the study intervention are excluded.
  19. Any concurrent anticancer treatment with the exception of bisphosphonates, denosumab for the treatment of bone metastases.

    Concurrent use of hormonal therapy for non cancer related conditions (eg, HRT) is allowed.

  20. Received prior radiotherapy to the chest within 4 weeks of the start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.
  21. Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.
  22. Curative radiotherapy; however, palliative radiotherapy for optimal symptom control or pain management is allowed.
  23. Concomitant use of chronic systemic (IV or oral) corticosteroids or other medications > 10 mg/day of prednisone or equivalent, except for managing AEs; inhaled steroids, intra-articular steroid injections, and other topical steroid formulations are permitted in this study.
  24. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within ≤ 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
  25. Participation in another clinical study with a study intervention or medicinal device administered in the last 4 weeks (unless the safety profile is known prior to the first dose of study intervention), enrolment into a prior Dato-DXd study regardless of treatment assignment, or concurrent enrolment in another clinical study (unless the study is observational [non-interventional], or the participant is in the follow-up period of an interventional study).
  26. Participants with a known history of severe reactions to either the drug or inactive (including but not limited to polysorbate 80) of Dato-DXd.
  27. Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies.
  28. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  29. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  30. Previous enrolment in the present study.
  31. For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding or planning to become pregnant.
  32. Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention.
  33. Participants for whom the use of steroid-containing mouthwash in .
Terms in these criteria, in plain language(37)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    single arm group

    All participants will receive Dato-DXd (6 mg/kg IV on Day 1, Q3W; up to a maximum of 540 mg Q3W for participants ≥ 90 kg) until investigator-defined disease progression according to RECIST 1.1 or until unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.

    Drug: Dato-DXd

Interventions

  • All participants will receive Dato-DXd (6 mg/kg IV on Day 1, Q3W; up to a maximum of 540 mg Q3W for participants ≥ 90 kg) until investigator-defined disease progression according to RECIST 1.1 or until unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met. Continued treatment with the same study drug post-progression may be allowed, based on prior discussion with sponsor/sponsor representative/study physician on a case-by-case basis following written investigator's confirmation of continuing clinical benefit to the patient post progression. The study is anticipated to enrol for an 18-month period, and DCO is expected to occur approximately 6 months after the last participant has been dosed.

    Also known as: IMP administration

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) per RECIST 1.1 as assessed by the investigator

    PFS is defined as time from date of first dose of study intervention until progression per RECIST 1.1 as assessed by the investigator or death due to any cause.

    Time frame: From date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, whichever occurs first, assessed up to approximately 24 months

Secondary outcomes

  1. Proportion of participants with oral mucositis/stomatitis

    Proportion of participants with oral mucositis/stomatitis

    Time frame: From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up)

  2. Proportion of participants with ocular events

    Proportion of participants with ocular events

    Time frame: From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up)

  3. Proportion of participants with Grade 3 or higher Adverse Events (AEs) possibly related to Dato-DXd treatment

    Grade 3 or higher adverse events possibly related to Dato-DXd treatment (Grade ≥ 3 treatment-related adverse events) according to NCI CTCAE 5.0. Possibly related is defined as reasonable possibility that the adverse event was caused by investigational product, as assessed by investigator. Missing responses are counted as possibly related.

    Time frame: From date of first dose of study intervention until 28 days after the last dose (Safety Follow-up)

  4. Clinical benefit rate (CBR) at 24 weeks

    CBR at 24 weeks is defined as the percentage of participants who have a confirmed CR or PR or who have SD per RECIST 1.1 as assessed by the investigator and derived from the raw tumour data for at least 24 weeks after date of first dose.

    Time frame: At 24 weeks after first dose

  5. Objective response rate (ORR)

    ORR is defined as the proportion of participants with measurable disease at baseline who have a confirmed CR or confirmed PR, as assessed by the investigator and derived from raw tumour data per RECIST 1.1.

    Time frame: From date of first dose until disease progression or death, whichever occurs first, assessed up to approximately 24 months

  6. Duration of response (DoR)

    DoR will be defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 as assessed by the investigator or death due to any cause. The analysis will include all dosed participants who have a confirmed response.

    Time frame: From the date of first documented confirmed response until disease progression per RECIST 1.1 or death from any cause, whichever occurs first, assessed up to approximately 24 months

  7. Overall survival (OS)

    OS defined as the time from the date of the first dose of study intervention until the date of death due to any cause. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy

    Time frame: From date of first dose of study intervention until death from any cause, assessed up to approximately 24-30 months

07

Study locations

39 of 40 sites recruiting
  • Research Site
    Largo, Florida 33770, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Fort Wayne, Indiana 46825, United States
    Recruiting
  • Research Site
    Omaha, Nebraska 68130, United States
    Recruiting
  • Research Site
    New York, New York 10021, United States
    Recruiting
  • Research Site
    Houston, Texas 77024, United States
    Recruiting
  • Research Site
    Puyallup, Washington 98373, United States
    Recruiting
  • Research Site
    Beijing, 100021, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Guangzhou, 510060, China
    Recruiting
  • Research Site
    Linyi, 276001, China
    Recruiting
  • Research Site
    Shandong, 250117, China
    Recruiting
  • Research Site
    Wuhan, 430071, China
    Recruiting
  • Research Site
    Zhengzhou, 450008, China
    Recruiting
  • Research Site
    Clermont-Ferrand, 63050, France
    Recruiting
  • Research Site
    La Roche-sur-Yon, 85925, France
    Recruiting
  • Research Site
    Montpellier, 34070, France
    Recruiting
  • Research Site
    Paris, 75005, France
    Recruiting
  • Research Site
    Pierre-Bénite, 69310, France
    Recruiting
  • Research Site
    Aviano, 33081, Italy
    Recruiting
  • Research Site
    Florence, 50134, Italy
    Recruiting
  • Research Site
    Meldola, 47014, Italy
    Recruiting
  • Research Site
    Milan, 20141, Italy
    Recruiting
  • Research Site
    Naples, 80131, Italy
    Recruiting
  • Research Site
    Roma, 00168, Italy
    Recruiting
  • Research Site
    Bukgu, 41404, South Korea
    Recruiting
  • Research Site
    Goyang-si, 410-769, South Korea
    Recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 06273, South Korea
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Recruiting
  • Research Site
    Seoul, 06591, South Korea
    Recruiting
  • Research Site
    Seoul, 136705, South Korea
    Recruiting
  • Research Site
    Seoul, 3722, South Korea
    Recruiting
  • Research Site
    Seoul, 5505, South Korea
    Recruiting
  • Research Site
    A Coruña, 15006, Spain
    Recruiting
  • Research Site
    Barcelona, 08035, Spain
    Recruiting
  • Research Site
    Granada, 18007, Spain
    Recruiting
  • Research Site
    Madrid, 28033, Spain
    Recruiting
  • Research Site
    Madrid, 28040, Spain
    Recruiting
  • Research Site
    Seville, 41009, Spain
    Recruiting
  • Research Site
    Valencia, 46009, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2028, 27 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 27 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Oct 3, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Feb 2, 2028
CompletionEst.
Feb 2, 2028
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Recruiting
Oct 2, 2026
Eligibility
4 inclusion criteria edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedInoperable or metastatic HR-positive, HER2 IHC 0 breast cancer (per ASCO/CAP guidelines, on local laboratory results); ie, is documented as HR-positive (either ER and/or PgR positive [ER or PgR ≥ 1%]) and HER2 IHC 0 (defined as including HER2 null with no staining or incomplete and faint/barely perceptible membrane staining in ≤ 10% of tumour cells) based on a fresh, or recent tissue sample obtained no more than 6 weeks prior to or during. Tumour status must be confirmed using the screening periodmost recent tumour biopsy (preferably fresh biopsy).
  • AddedA fresh biopsy may only be omitted if not medically feasible due to documented clinical reasons, such as anatomical inaccessibility, unacceptable procedural risk, or patient refusal after appropriate discussion. In such cases, the most recent available tumour sample may be used. The specific reason for not obtaining a fresh biopsy must be prospectively documented and may be subject to sponsor review.
  • EditedProvision of acceptable tumour sample (newly acquired tumour biopsy at baseline or a tumourthe latest archival biopsy sample collected within 6 weeks prior to screeningavailable if a fresh biopsy is not feasible) as defined in the Laboratory Manual
  • EditedStarting at the time of first dose of Dato-DXd, male participants must not freeze or donate sperm at any time during this studythroughout the duration of treatment and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to the first dose of study intervention.
  • EditedStarting at the time of first dose of Dato-DXd, female participants must not donate, or retrieve for their own use, ova at any time during this studythroughout the duration of treatment and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to the first dose of study intervention.
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Research Site is now Recruiting
    Eligibility 4 inclusion criteria edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedInoperable or metastatic HR-positive, HER2 IHC 0 breast cancer (per ASCO/CAP guidelines, on local laboratory results); ie, is documented as HR-positive (either ER and/or PgR positive [ER or PgR ≥ 1%]) and HER2 IHC 0 (defined as including HER2 null with no staining or incomplete and faint/barely perceptible membrane staining in ≤ 10% of tumour cells) based on a fresh, or recent tissue sample obtained no more than 6 weeks prior to or during. Tumour status must be confirmed using the screening periodmost recent tumour biopsy (preferably fresh biopsy).
    • AddedA fresh biopsy may only be omitted if not medically feasible due to documented clinical reasons, such as anatomical inaccessibility, unacceptable procedural risk, or patient refusal after appropriate discussion. In such cases, the most recent available tumour sample may be used. The specific reason for not obtaining a fresh biopsy must be prospectively documented and may be subject to sponsor review.
    • EditedProvision of acceptable tumour sample (newly acquired tumour biopsy at baseline or a tumourthe latest archival biopsy sample collected within 6 weeks prior to screeningavailable if a fresh biopsy is not feasible) as defined in the Laboratory Manual
    • EditedStarting at the time of first dose of Dato-DXd, male participants must not freeze or donate sperm at any time during this studythroughout the duration of treatment and for at least 4 months after the last dose of Dato-DXd. Preservation of sperm should be considered prior to the first dose of study intervention.
    • EditedStarting at the time of first dose of Dato-DXd, female participants must not donate, or retrieve for their own use, ova at any time during this studythroughout the duration of treatment and for at least 7 months after the last dose of Dato-DXd. Preservation of ova should be considered prior to the first dose of study intervention.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07205822
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Oct 30, 2025
Primary completion
Feb 2, 2028 (estimated)
Completion
Feb 2, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Datopotamab deruxtecan

Start the discussion